Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial
Study context
- Population
- Patients with active cancer scheduled to undergo an anthracycline-based chemotherapy regimen; patients with prior HF or cardiomyopathy excludedplanned enrollment
- Participants
- 1,018 patients
- Planned comparison
- Carvedilol vs placebo
- Primary endpoint
- Composite of:
- New left ventricle ejection fraction (LVEF) reduction by at least 10% leading to an LVEF <50%
- Cardiovascular death
- Myocardial infarction
- Urgent care visit or hospitalization for heart failure
- Clinically significant arrhythmias
- Follow-up
- 12 months
Methodological details25 study sites in Brazil, 1:1 ratio, stratified by site and use of renin-angiotensin blockers at baseline, central core lab, clinical outcomes will be adjudicated
- 25 study sites in Brazil
- 1:1 ratio
- Stratified by site and use of renin-angiotensin blockers at baseline
- Central core lab
- Clinical outcomes will be adjudicated
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial. Am Heart J. Published 22 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it